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OPINION Open Access
Prevention and management of CVD in
LMICs: why do ethnicity, culture, and
context matter?
Shuchi Anand1, Christina Bradshaw1 and Dorairaj Prabhakaran2,3,4*
Abstract
Background: Low- and middle-income countries now experience the highest prevalence and mortality rates of
cardiovascular disease.
Main text: While improving the availability and delivery of proven, effective therapies will no doubt mitigate this
burden, we posit that studies evaluating cardiovascular disease risk factors, management strategies and service
delivery, in diverse settings and diverse populations, are equally critical to improving outcomes in low- and middle-
income countries. Focusing on examples drawn from four cardiovascular diseases— coronary artery disease, stroke,
diabetes and kidney disease — we argue that ethnicity, culture and context matter in determining the risk factors
for disease as well as the comparative effectiveness of medications and other interventions, particularly diet and
lifestyle interventions.
Conclusion: We believe that a host of cohort studies and randomized control trials currently being conducted or
planned in low- and middle-income countries, focusing on previously understudied race/ethnic groups, have the
potential to increase knowledge about the cause(s) and management of cardiovascular diseases across the world.
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Background
The majority of the rich, decades-long epidemiology data
on risk factors for cardiovascular disease (CVD) has been
obtained from studies in high-income settings [1–4]. These
studies subsequently created the fundamental knowledge
base to propel highly effective CVD interventions, including
life-style interventions, antihypertensives, lipid-lowering sta-
tins, and antiproteinuric renin-angiotensin system blockers.
However, a substantial burden of CVD persists, which is
much higher in low- and middle-income countries (LMICs)
than in high-income countries [5]; close to 80% of CVD
deaths occur in LMICs, and nearly 40% of these are labeled
as premature [5]. This is despite the lower prevalence of
cardiovascular risk factors such as high blood pressure,
obesity, diabetes and dyslipidemia in LMICs. One obvious
explanation is the lack of resources to effectively deliver
proven therapies. Herein, we lay out a case for probing
beyond resource paucity as the chief driver for variation in
cardiovascular risk and/or outcomes in diverse populations
in the world.
Focusing on four categories of CVD — coronary artery
disease, stroke, diabetes and kidney disease — we highlight
recently established or emerging risk factors for CVD
retrieved from studies performed in ethnically diverse pop-
ulations. We also discuss the importance of studies evaluat-
ing comparative effectiveness of established therapies given
data demonstrating differences in response by race/ethni-
city. Finally, we provide the rationale for clinical trials evalu-
ating region-specific and innovative models of care delivery.
All of this work, we believe, has the potential to expand the
scientific knowledge base informing strategies to combat
CVD. Figure 1 lays out the conceptual basis for our
argument.
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Risk factors for CVD: why we need studies in
diverse populations, in diverse regions of the
world
While clinicians have long recognized that prevalence of
specific CVDs varies by race, ethnicity or geography
(Table 1 demonstrates, for example, the high and growing
prevalence of hypertension in low-income countries), only
recently has there been intensive research focus to investi-
gate the reasons for these variations; whether these are
genetically or culturally based, understanding them has
been ‘game-changing’ for some fields.
One of the most prominent examples arises from the
kidney disease literature. It was well-established that
African Americans have up to fourfold the risk for end-
stage kidney disease compared with Caucasians [7], with
hypertensive nephrosclerosis [8] and focal segmental glo-
merulosclerosis [9] occurring at much higher frequencies
in African Americans. A decade-long search for a possible
genetic basis led to the discovery of Apolipoprotein
(APOL)-1 polymorphisms [10, 11], present in up to 30%
of some ethnic groups in West Africa [12], which concur-
rently protect against sleeping sickness but confer a higher
risk for hypertensive nephrosclerosis or focal segmental
glomerulosclerosis in West African compared with Cauca-
sian or East African populations. This discovery has not
only changed our understanding of risk for end-stage
kidney disease in African Americans (prior hypotheses
had largely centered around access to care), it is also
affecting risk stratification for kidney transplant [13]. A
difference in the causes of kidney disease but not neces-
sarily overall prevalence exists for other ethnicities and
regions [14], including for IgA nephropathy, the most
common cause of glomerulonephritis in the world and
which has a well-established predilection for Asian and
Mediterranean populations. Intense efforts are underway
to identify a genetic basis [15].
The prevalence and risk for diabetes also varies widely
by ethnicity. In Hispanic and Latino populations in the
Fig. 1 Conceptual basis for ethnicity and cultural context in cardiovascular disease (CVD). SES socioeconomic status
Table 1 Prevalence of risk factors by country income groups
Risk factors, % of population Low income Low middle income Upper middle income High income
Tobacco use, men 31 32 43 33
Tobacco use, women 3 3 5 18
Insufficient physical activity 17 17 25 33
Overweight 21 27 43 56
High blood pressure 28 25 20 19
High cholesterol 24 32 46 59
High fasting glucose 7 9 9 7
Populations referred to are adults 18 years or older, except for tobacco use (15 years or older) and high cholesterol (25 years or older). Overweight defined as
body mass index ≥25 kg/m2, high blood pressure as ≥140mmHg (systolic) or > 90mmHg (diastolic), high cholesterol as ≥5.0 mmol/L, and high fasting glucose
as ≥7.0 mmol/L.
Adapted from [6]
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USA, diabetes prevalence nears twofold that of US
Caucasians [16]. Genome-wide analysis studies focused
specifically on the Mexican and Mexican American
populations identified a candidate locus that could result
in disordered lipid metabolism; this locus occurs at high
frequency in Native American and East Asian popula-
tions but is rare in Caucasians [17]. Other work from
the Pima Indian population — nearly 50% of whom have
diabetes — identified a locus that predisposes to high
birthweight and confers a twofold increase in the risk for
type 2 diabetes [18]. A recent study comparing insulin
profiles in two high-risk ethnic groups found a higher
propensity for insulin resistance, as measured by
HOMA-IR, among Pima Indians compared with Asian
Indians, who had substantially lower insulin secretion
[19]. Thus, understanding the mechanisms (genetic, fetal
programming or environmental) that operate in a given
ethnic group could help stratify whether patients are
likely to have perturbations in insulin secretion versus
resistance, and thus allow for tailored initial therapy.
Studies evaluating risk factors in diverse populations
can also highlight cross-cultural differences in diet or
lifestyle that result in variations in disease patterns. In
an early study comparing mortality and risk factors in
three regions of the world (Finland, China, and USA)
[20], the authors discovered striking differences in total
cholesterol (highest in Finland and lowest in China) and
ischemic heart disease mortality (age-standardized
mortality rate nearly tenfold higher in Finland than in
China). On the other hand, dietary salt intake and age-
standardized stroke mortality was substantially higher in
China in this and in many other larger analyses [21].
The Prospective Urban RurEpidemiology (PURE) study
is perhaps one of the largest and longest running exam-
ples of an attempt to explore the complex interactions
between cultural and genetic CVD risk factors and the
likelihood of events in 17 countries across the income
spectrum [22]. Despite a lower prevalence of tradition-
ally recognized risk factors in LMICs, PURE investiga-
tors observed higher event rates in LMICs than in high-
income countries [23], providing impetus to investigate
‘non-traditional’ risk factors that could be contributing
to higher event rates in LMICs.
Several hypothesized non-traditional risk factors, such
as low birthweight, air pollution, and occupational expo-
sures, including to pesticides and heat stress, may
contribute to burden of disease across the world but
could be better studied in LMICs due to the higher like-
lihood of exposure in these settings. The US National
Institutes of Health Fogarty Institute has funded seven
‘Geo-health’ collaborations across the world to evaluate
the contribution of environmental (e.g., outdoor and in-
door air pollution) and occupational exposures (e.g., in
street vendors or electronic waste recycling workers) to
human disease. International consortia have formed to
investigate the cause of a chronic kidney disease of
unknown etiology among agricultural workers living in
lowland areas [24], a disease more common in certain
LMICs but possibly occurring at lower intensity and/or
frequency in high-income countries as well.
Interventions for CVD: why drugs and models of
care may need region-specific fine tuning
Similar to epidemiologic data on CVD, the evidence for
its therapeutic interventions has largely been derived
from high-income settings. However, just as CVD
phenotypes may vary by race and ethnicity, so does the
effectiveness of therapies for CVD and associated risk
factors.
Clinicians have long recognized that antihypertensives
have disparate blood pressure lowering effects by race/
ethnicity [25], yet few observational studies or clinical
trials have been designed to directly compare effective-
ness across these strata. In fact, application of therapies
without a trial has led to inappropriate treatment guide-
lines. For example, the South Asian ethnicity is charac-
terized by high triglycerides, low HDL cholesterol, high
propensity to diabetes, and low physical activity [26].
Based on prior Western guidelines, the Indian Society of
Hypertension advocated beta-blockers (which have all
the side effects mentioned above) as the first line treat-
ment [27]. Furthermore, nuanced effects of combination
antihypertensive therapy are often not apparent without
race- or ethnicity-specific data; secondary subgroup
analyses have demonstrated preliminary evidence for
variable blood pressure-lowering results upon addition
of a second antihypertensive agent, depending not only
on the pharmacologic regimen but also on race/ethnicity
[28]. The recently completed CREOLE study represents
one of the only examples of a study whose primary aim
was to determine race-specific treatment strategies for
high blood pressure. This study found that combination
regimens, including calcium channel blockers, were more
effective than a regimen based on renin-angiotensin
system blockade and thiazide diuretics in sub-Saharan
Africa [29]. None of these studies have been launched to
compare initial blood pressure treatment strategies in
other races or ethnicities. Clearly, the differential effects of
pharmacologic agents on blood pressure by race can
influence the downstream risk for CVD events, perhaps
most famously shown by the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALL-
HAT), in which African Americans in the renin-
angiotensin blockers arm experienced higher risk for
strokes and other CVD events [30].
With the emergence of evidence that South Asians
exhibit a different diabetes phenotype [19], the choice of
pharmacologic therapy for glycemic control in diabetes
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or pre-diabetes should ideally account for ethnic factors.
Data suggest that dipeptidyl peptidase-4 inhibitors are
more effective at lowering hemoglobin A1c values and
fasting plasma glucose in Asians versus non-Asians with
type 2 diabetes mellitus [31]. Differences in glycemic
response exist even in patients with impaired glucose
tolerance; in a study of patients treated with rosiglita-
zone for prevention of diabetes, the magnitude of risk
reduction for developing diabetes was mediated by
ethnicity, with Hispanics experiencing a much greater
risk reduction than South Asians [32]. While rosiglita-
zone is no longer widely used, the ethnicity and
effectiveness interaction observed in the DREAM trial
supports that antidiabetic medications in other classes
should undergo similar evaluations. Although the
effectiveness of sodium glucose co-transporter 2 inhibi-
tors has not been shown to significantly differ by race
[33, 34], a larger number of well-powered studies of di-
verse populations are needed to validate this finding.
Perhaps as important as the differential effects of
pharmacologic therapies for CVD are the sociocultural
context and healthcare systems in which these therapies
are delivered. Reliable access to healthcare in LMICs,
particularly in rural areas, continues to be a challenge
and, in contrast to high-income countries, the average
person has minimal interaction with primary care pro-
viders who could conduct CVD risk screening. However,
efforts are ongoing to improve primary healthcare deliv-
ery in LMICs, with community health outreach models
that task-shift to local health workers showing success
[35]. Recent meta-analyses have found substantial
evidence for the effectiveness of lifestyle interventions,
key examples of which have led to a twofold higher like-
lihood of tobacco cessation [36] or improved knowledge
regarding complications of type 2 diabetes [37]. These
innovative lower-cost models have high potential,
particularly to engage with evolving technologies such as
artificial intelligence, and may inform the evolving role
of ‘physician-extenders’ in high-income countries.
However, they nonetheless require integration within a
larger, better supported healthcare system [38]. Many
LMICs are making ambitious steps towards universal
health care [39, 40], with Thailand integrating country-
specific, health technology cost-effectiveness assessments
into the development of a successfully implemented uni-
versal healthcare package [41].
Devoting more resources to the healthcare system is
not enough on its own to improve CVD care; rather,
awareness and integration of cultural norms and family
structures into treatment plans is also necessary to pro-
vide effective care, especially that targeted at prevention
and/or lifestyle modification. Interventions for physical
activity in Brazil, for example, may be more effective if
inclusive of football/soccer, since recreational football/
soccer use is common in men and holds a positive
cultural value [42], whereas other forms (e.g., yoga) may
be more acceptable for South Asians [43]. Family mem-
bers and other social support networks are crucial
mediators of dietary and physical activity interventions
as well as of medication adherence, especially for type 2
diabetes [44]. Clearly, these ecosystems and their
interplay with the patient vary across the world, with
different family members, for example, making food-
purchasing or leisure-time activity decisions. Not only
would the intervention design need to be tailored, but
the relative effectiveness may vary depending on the
region and/or race/ethnicity. Thus, a specific region may
find it more cost-effective and worthwhile to invest in
family-based lifestyle interventions, whereas another may
want to focus on medication availability and delivery.
Conclusion
Since CVDs are recognized as a major cause of poor
health in all regions of the world, researchers now have
a strong rationale to investigate the differences in risk
factors and management strategies. Data increasingly
support the likelihood that genetic, cultural, and envir-
onmental variations exist in causes of CVD by race and
ethnicity. These variations should be accounted for when
devising strategies for the prevention and treatment of
CVD. Clinical trials and observational studies designed
specifically to probe differences across race/ethnicity
strata are crucial to improving CVD care across the
world.
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